Target Price | $385.92 |
Price | $368.00 |
Potential | 4.87% |
Number of Estimates | 36 |
36 Analysts have issued a price target Visa 2026 . The average Visa target price is $385.92. This is 4.87% higher than the current stock price. The highest price target is $440.00 19.57% , the lowest is $305.00 17.12% . | |
A rating was issued by 43 analysts: 34 Analysts recommend Visa to buy, 9 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Visa stock has an average upside potential 2026 of 4.87% . Most analysts recommend the Visa stock at Purchase. |
36 Analysts have issued a sales forecast Visa 2025 . The average Visa sales estimate is $39.5b . This is 5.03% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $40.0b 6.32% , the lowest is $39.1b 3.80% .
This results in the following potential growth metrics:
2024 | $35.9b | 10.02% |
---|---|---|
2025 | $39.5b | 9.99% |
2026 | $43.7b | 10.51% |
2027 | $47.9b | 9.67% |
2028 | $52.5b | 9.58% |
20 Analysts have issued an Visa EBITDA forecast 2025. The average Visa EBITDA estimate is $27.9b . This is 6.87% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $28.9b 10.38% , the lowest is $27.3b 4.59% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $25.1b | 9.71% |
---|---|---|
2025 | $27.9b | 11.38% |
2026 | $30.8b | 10.37% |
2027 | $33.9b | 10.01% |
2028 | $37.1b | 9.23% |
2024 | 69.84% | 0.28% |
---|---|---|
2025 | 70.72% | 1.26% |
2026 | 70.63% | 0.13% |
2027 | 70.85% | 0.31% |
2028 | 70.62% | 0.32% |
24 Visa Analysts have issued a net profit forecast 2025. The average Visa net profit estimate is $23.0b . This is 16.87% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $24.2b 23.08% , the lowest is $22.3b 13.74% .
This results in the following potential growth metrics and future Net Margins:
2024 | $19.5b | 14.53% |
---|---|---|
2025 | $23.0b | 17.98% |
2026 | $27.0b | 17.59% |
2027 | $30.5b | 12.93% |
2028 | $34.0b | 11.48% |
2024 | 54.16% | 4.09% |
---|---|---|
2025 | 58.09% | 7.26% |
2026 | 61.82% | 6.42% |
2027 | 63.65% | 2.96% |
2028 | 64.75% | 1.73% |
24 Analysts have issued a Visa forecast for earnings per share. The average Visa EPS is $10.77 . This is 8.13% higher than earnings per share in the financial year 2024. The highest EPS forecast is $11.34 13.86% , the lowest is $10.48 5.22% .
This results in the following potential growth metrics and future valuations:
2024 | $9.58 | 17.69% |
---|---|---|
2025 | $10.77 | 12.42% |
2026 | $12.66 | 17.55% |
2027 | $14.30 | 12.95% |
2028 | $15.94 | 11.47% |
Current | 36.95 | 20.42% |
---|---|---|
2025 | 34.18 | 7.49% |
2026 | 29.06 | 14.98% |
2027 | 25.74 | 11.42% |
2028 | 23.09 | 10.30% |
Based on analysts' sales estimates for 2025, the Visa stock is valued at an EV/Sales of 18.24 and an P/S ratio of 18.06 .
This results in the following potential growth metrics and future valuations:
Current | 19.15 | 19.31% |
---|---|---|
2025 | 18.24 | 4.77% |
2026 | 16.50 | 9.51% |
2027 | 15.05 | 8.82% |
2028 | 13.73 | 8.75% |
Current | 18.97 | 18.78% |
---|---|---|
2025 | 18.06 | 4.79% |
2026 | 16.34 | 9.51% |
2027 | 14.90 | 8.82% |
2028 | 13.60 | 8.75% |
Analyst | Rating | Action | Date |
---|---|---|---|
Truist Securities |
➜
Buy
|
Initiated | Jun 02 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | May 28 2025 |
Jefferies |
Buy
➜
Buy
|
Unchanged | May 27 2025 |
Macquarie |
Outperform
➜
Outperform
|
Unchanged | Apr 30 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Apr 30 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | Apr 30 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 30 2025 |
Analyst Rating | Date |
---|---|
Initiated
Truist Securities:
➜
Buy
|
Jun 02 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
May 28 2025 |
Unchanged
Jefferies:
Buy
➜
Buy
|
May 27 2025 |
Unchanged
Macquarie:
Outperform
➜
Outperform
|
Apr 30 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Apr 30 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
Apr 30 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Apr 30 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.